SVFC $$$$ IntelliCell Biosciences Engages MD Global Partners, LLC as Advisor to the Company
NEW YORK, NY--(Marketwired - Oct 10, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular fraction cells (SVFCs) derived from the blood vessels in lipoaspirate, announced today that it has engaged MD Global Partners, LLC to advise on the company's restructuring, corporate positioning, and strategic opportunities.
The influx of capital structure will allow, the Company to expand its FDA cGTP cellular laboratories into Hospitals and Ambulatory Surgical Centers. This will also enable IntelliCell to initiate a FDA IND clinical study, vital for the development of the company.
Dr. Steven Victor said, "I am privileged that Mr. Owen May, Managing Director of MD Global Partners, is going to lead in the Company's restructuring and strategic positioning. With his years of experience and expertise, Mr. May will be instrumental in assisting us to achieve our strategic milestones. Mr. May, a graduate of Duke University's Fuqua School of Business, is a seasoned professional with decades of experience in helping assisting emerging growth companies, similar to IntelliCell achieve their goals."
Dr. Steven Victor, Chairman and CEO of IntelliCell Biosciences, commented, "IntelliCell believes that we possess a paradigm shifting discovery that will change the manner in which patients are treated," Dr. Victor continued. "We are confident that our relationships with the FDA and other governing bodies will allow us to rapidly expand the number of patients that physicians at ReGen Medical, PC can treat using IntelliCell's SFV cellular therapy."
About MD Global Partners
MD Global Partners, LLC ("MDG") is an independent full service investment bank focused on small to middle market public and private companies. The Firm brings an integrated strategic, operating and financial approach in assisting small companies realize the benefits of conventional investment banking services throughout the life cycle. Its senior team has extensive transaction execution experience and strong relationships with a variety of investors including family offices and individual/institutional investors, both domestic and global. MDG's wide spectrum of service offerings combined with its global, diverse investor network, uniquely positions itself to provide advice and find optimal investor groups to its clients.
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. One of the revenue streams IntelliCell is pursuing is placing its labs into Hospitals and Ambulatory Surgical Centers. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Much more likely...as long as speculations are made...that a private investor...or MD Global may be assisting. Let's look at the available information....and connect the dots.
GO SVFC
Market Data 
Markets 
AI
